Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK5764227 |
Synonyms | |
Therapy Description |
Limited information is currently available on GSK5764227, a putative antibody-drug conjugate (ADC) targeting CD276 (B7-H3) (Aug 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK5764227 | GSK 5764227|GSK-5764227 | Limited information is currently available on GSK5764227, a putative antibody-drug conjugate (ADC) targeting CD276 (B7-H3) (Aug 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06551142 | Phase I | GSK5764227 Topotecan | A Study of GSK5764227 in Participants With Advanced Solid Tumors | Not yet recruiting | USA | ITA | GBR | FRA | ESP | CAN | ARG | 1 |